Citadel Advisors
QNRX

Citadel Advisors’s Quoin Pharmaceuticals QNRX Stock Holding History

Citadel Advisors’s Portfolio QNRX Stock Details QNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-32,519
Closed -$215K – 14636
2026
Q1 		$215K Buy
+32,519
New +$295K ﹤0.01% 11278
2024
Q2 		– Sell
-308
Closed -$10.2K – 15188
2024
Q1 		$10.2K Buy
+308
New +$30.4K ﹤0.01% 13467
2023
Q1 		– Sell
-25
Closed -$15.1K – 15358
2022
Q4 		$15.1K Sell
25
-17
-40% -$12.8K ﹤0.01% 13346
2022
Q3 		$39K Buy
42
+38
+950% +$78.2K ﹤0.01% 11772
2022
Q2 		$9K Buy
+4
New +$15.9K ﹤0.01% 12605
2021
Q3 		– Sell
-1
Closed -$60K – 14483
2021
Q2 		$60K Hold
1
– – ﹤0.01% 13249
2021
Q1 		$52K Buy
+1
New +$69.8K ﹤0.01% 12886
2019
Q4 		– Hold
0
– -$12K – 9626
2019
Q3 		– Hold
0
– – – 9024
2019
Q2 		– Hold
0
– – – 8983
2019
Q1 		– Hold
0
– -$62K – 9754
2018
Q4 		– Hold
0
– – – 8431

Other funds holding QNRX

DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Citadel Advisors's QNRX Position: Q2 2026 in Review

Citadel Advisors sold out of Quoin Pharmaceuticals (QNRX) in Q2 2026, closing a stake of 32,519 shares — an estimated $215K sold.

Citadel Advisors first reported a position in QNRX in Q1 2021 and held it in 7 quarters. The position peaked at $215K in Q1 2026. 20 funds tracked by Wall St. Rank hold QNRX as of Q2 2026.

  • Citadel Advisors reported no remaining Quoin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 32,519 Quoin Pharmaceuticals shares in Q2 2026, an estimated $215K.
  • Citadel Advisors first reported a position in Quoin Pharmaceuticals in Q1 2021 and held it in 7 quarters.
  • Citadel Advisors's Quoin Pharmaceuticals position peaked at $215K in Q1 2026.
  • 20 funds tracked by Wall St. Rank held Quoin Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.